Citations

Mayo Clinic

Showing 10 of 108585 citations.

Clinical and imaging outcomes of 100 patients with cerebrospinal fluid-venous fistulas treated by transvenous embolization
Brinjikji, Waleed , Garza, Ivan , Whealy, Mark , Mark, Ian T. , Morris, Pearse , Verdoorn, Jared T. , Benson, John C. , Atkinson, John L. D., Cutsforth‐Gregory, Jeremy K. , Madhavan, Ajay, Mark, Ian , Morris, Pearse P, Verdoorn, Jared T , Benson, John , Kobeissi, Hassan , Cutsforth-Gregory, Jeremy K , Madhavan, Ajay A. , Kissoon, Narayan , Kobeissi, Hassan

Journal of NeuroInterventional Surgery | October 28, 2023 | Volume: 16 | Issue: 12 | Pages: 1256-1263

10.1136/jnis-2023-021012 | PMID 37898553 Get It

Background Cerebrospinal fluid-venous fistulas (CSFVF) are a common cause of spontaneous intracranial hypotension (SIH). Transvenous embolization has emerged as a reliable treatment option. We review the clinical presentation, imaging, and clinical outcomes of 100 consecutive CSFVF patients who underwent embolization over 2 years. Methods Baseline clinical characteristics, imaging findings (including Bern SIH score), technical outcomes, and long-term imaging and clinical outcomes were collected. All patients had at least 3 months of clinical follow-up and had baseline MRI. 99/100 patients underwent follow-up imaging at ≥3 months post-treatment. Results 100 patients were included. Mean imaging and clinical follow-up duration was 8.3±7.7 months and 15.0±6.8 months, respectively. The mean duration of symptoms before embolization was 40.9±52 months. Mean baseline Bern SIH score was 5.9±3.3. The most common baseline symptoms were headache (96 patients), tinnitus (55 patients), and cognitive dysfunction (44 patients). Technical success rate was 100%. Mean post-treatment Bern SIH score was 0.9±1.6 (P<0.0001). Following treatment, 95% of patients reported significant improvement or resolution in symptoms (58 patients reporting resolution and 37 reporting improvement). 5 patients reported no improvement. There were no major procedural or periprocedural complications. 10 patients had minor procedural complications that did not result in any change in management (Onyx emboli, venous perforation). 19 patients had rebound intracranial hypertension requiring acetazolamide therapy. 7 patients had recurrent fistula at the initially treated level. Conclusions Transvenous embolization of CSFVF in SIH patients is safe and effective with a 95% treatment response, significant improvement in imaging outcomes, and a very low rate of complications.
Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm
Brennan, Paul , Zelber‐Sagi, Shira , Dillon, John , Lazarus, Jeffrey V. , Dillon, John F , Lazarus, Jeffrey V , Brennan, Paul N , Allen, Alina M.

Gut | October 28, 2023 | Volume: 73 | Issue: 4 | Pages: 560-563

10.1136/gutjnl-2023-330771 | PMID 37898546 Get It

Determining call-to-entry rate and recruitment barriers in clinical studies for community clinics serving low-income populations: a cohort study
Vaughan, Elizabeth M. , Cardenas, Victor J. , Porterfield, Laura , Delgado, Zuleica Santiago , Samson, Susan L. , Schick, Vanessa , Naik, Aanand D. , Virani, Salim S. , Rifai, Mahmoud Al , Johnston, Craig Allen

BMJ Open | October 28, 2023 | Volume: 13 | Issue: 10 | Pages: e077819

10.1136/bmjopen-2023-077819 | PMID 37898484 Get It

Background Recruitment for clinical studies is challenging. To overcome barriers, investigators have previously established call-to-entry rates to assist in planning. However, rates specific to low-income minority populations are needed to account for additional barriers to enrolment these individuals face. Objective To obtain a call-to-entry rate in a low-income uninsured Hispanic population with chronic disease. Methods We used data from four of our randomised clinical studies to determine the call-to-entry rate for individuals (n=1075) with or at risk for type 2 diabetes: participants needed/potential participants contacted=recruitment rate (yield). Research staff contacted potential participants to enrol in a study that evaluated 6 month diabetes programmes at community clinics from 2015 to 2020. We recorded call-to-entry rates, reasons for declining the study, show rates, and attrition. Results The call-to-entry rate was 14.5%. Forty per cent of potential participants could not be contacted, and 30.6%, 19.1%, and 5.4% responded yes , no , and maybe , respectively. No show percentages were 54% for yes and 91.4% for maybe responders. The majority (61.6%) declined due to inability to attend; reasons to decline included work (43%), eligibility (18%), transportation (10%), out of town (9%), did not think they needed the programme (7%) and other/unknown (14%). Being a physician predicted inability to reach participants (adjusted OR 2.91, 95% CI 1.73 to 4.90). Attrition was 6.8%. Conclusions We described a call-to-entry rate and detailed recruitment data, including reasons to decline the study. This valuable information can assist investigators in study planning and overcoming enrolment barriers in low-income populations. Telehealth-based or strategies that limit transportation needs may increase participant involvement. Trial registration number NCT03394456 .
Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia
Kuchenbecker, Lindsey A. , Tipton, Philip W. , Martens, Yuka A. , Brier, Matthew R. , Satyadev, Nihal , Dunham, Steven , Lazar, Evelyn, Dacquel, Maxwell V., Henson, Rachel L. , Geschwind, Michael D., Morris, John C. , Herries, Elizabeth, Graff‐Radford, Neill R. , Day, Gregory S. , Martens, Yuka, Dunham, S Richard , Lazar, Evelyn B, Day, Gregory S , Tipton, Philip W , Morris, John C , Satyadev, N , Bu, Guojun , Schindler, Suzanne E.

Annals of Neurology | October 28, 2023 | Volume: 95 | Issue: 2 | Pages: 299-313

10.1002/ana.26822 | PMID 37897306 Get It

ObjectiveThis study was undertaken to apply established and emerging cerebrospinal fluid (CSF) biomarkers to improve diagnostic accuracy in patients with rapidly progressive dementia (RPD). Overlap in clinical presentation and results of diagnostic tests confounds etiologic diagnosis in patients with RPD. Objective measures are needed to improve diagnostic accuracy and to recognize patients with potentially treatment‐responsive causes of RPD.MethodsBiomarkers of Alzheimer disease neuropathology (amyloid‐β 42/40 ratio, phosphorylated tau [p‐tau181, p‐tau231]), neuroaxonal/neuronal injury (neurofilament light chain [NfL], visinin‐like protein‐1 [VILIP‐1], total tau), neuroinflammation (chitinase‐3‐like protein [YKL‐40], soluble triggering receptor expressed on myeloid cells 2 [sTREM2], glial fibrillary acidic protein [GFAP], monocyte chemoattractant protein‐1 [MCP‐1]), and synaptic dysfunction (synaptosomal‐associated protein 25kDa, neurogranin) were measured in CSF obtained at presentation from 78 prospectively accrued patients with RPD due to neurodegenerative, vascular, and autoimmune/inflammatory diseases; 35 age‐ and sex‐matched patients with typically progressive neurodegenerative disease; and 72 cognitively normal controls. Biomarker levels were compared across etiologic diagnoses, by potential treatment responsiveness, and between patients with typical and rapidly progressive presentations of neurodegenerative disease.ResultsAlzheimer disease biomarkers were associated with neurodegenerative causes of RPD. High NfL, sTREM2, and YKL‐40 and low VILIP‐1 identified patients with autoimmune/inflammatory diseases. MCP‐1 levels were highest in patients with vascular causes of RPD. A multivariate model including GFAP, MCP‐1, p‐tau181, and sTREM2 identified the 44 patients with treatment‐responsive causes of RPD with 89% accuracy. Minimal differences were observed between typical and rapidly progressive presentations of neurodegenerative disease.InterpretationSelected CSF biomarkers at presentation were associated with etiologic diagnoses and treatment responsiveness in patients with heterogeneous causes of RPD. The ability of cross‐sectional biomarkers to inform upon mechanisms that drive rapidly progressive neurodegenerative disease is less clear. ANN NEUROL 2024;95:299–313
Progress in precision pediatric surgical oncology
Polites, Stephanie F.

Cancer | October 28, 2023 | Volume: 129 | Issue: 24 | Pages: 3852-3853

10.1002/cncr.35073 | PMID 37897678 Get It

The increasingly targeted and personalized care of pediatric solid tumors extends to the surgical realm. Enhancing sentinel lymph node biopsy with fluorescence‐guided surgery is one example of this innovation in pediatric surgical oncology.
Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies
Bouchal, Samantha M. , Power, Erica A. , Nonnenbroich, Leo F., Rechberger, Julian S. , Nesvick, Cody L. , Power, Erica A , Bouchal, Samantha M , Daniels, David J.

Expert Opinion on Therapeutic Targets | October 28, 2023 | Volume: 27 | Issue: 11 | Pages: 1071-1086

10.1080/14728222.2023.2277232 | PMID 37897190 Get It

A systematic review and meta‐analysis of diet and nutrient intake in adults with irritable bowel syndrome
Veraza, Diego Izquierdo, Jansson‐Knodell, Claire , Aljaras, Rawan, Biruete, Annabel , Shin, Andrea , Calderon, Gerardo, Shin, Andrea , Calderon-Lopez, Gerardo , Aljaras, Rawan, Foster, Erin D. , Xu, Huiping

Neurogastroenterology & Motility | October 28, 2023 | Volume: 36 | Issue: 1 | Pages: No page available

10.1111/nmo.14698 | PMID 37897138 Get It

AbstractBackgroundNumerous individual and environmental factors including diet may play an important role in the pathophysiology of irritable bowel syndrome (IBS). It is unclear to what degree dietary intake is affected in individuals with IBS. We aimed to perform a systematic review and meta‐analysis to summarize dietary intake of adults with IBS and to compare dietary intake between adults with IBS and non‐IBS controls.MethodsOvid MEDLINE, Embase, Cochrane, CINAHL, and Scopus were searched through February 2023 for clinical trials and observational studies measuring usual diet in adults with IBS. Pooled weighted averages were estimated for total energy, macronutrient, and micronutrient data. Mean differences (MD) in nutrient intake were estimated for adults with IBS versus non‐IBS controls using a random effects model. Heterogeneity was assessed by the inconsistency index (I2).Key ResultsSixty‐three full‐text articles were included in the review of which 29 studies included both IBS and control subjects. Nutrients not meeting the recommended intake level for any dietary reference values in the IBS population were fiber and vitamin D. Meta‐regression by female proportion was positively correlated with total fat intake and negatively correlated with carbohydrate intake. Comparisons between participants with IBS and controls showed significantly lower fiber intake in participants with IBS with high heterogeneity (MD: −1.8; 95% CI: −3.0, −0.6; I2 = 85%).Conclusions and InferencesThis review suggests that fiber and vitamin D intake is suboptimal in IBS; however, overall dietary intake does not appear to be comprised. Causes and consequences of reduced fiber in IBS deserve further study.Results of this systematic review and meta‐analysis suggest that fiber and vitamin D intake is suboptimal in IBS. However, overall intake of other macro‐ and micronutrients does not appear to be compromised. Causes and consequences of reduced fiber and Vitamin D intake in IBS deserve further study.
In pursuit of personalized medicine in fibrotic interstitial lung diseases. Divide and conquer
Tzilas, Vasilios , Bouros, Demosthenes , Ryu, Jay H. , Ryu, Jay H

Pulmonology | October 28, 2023 | Volume: 30 | Issue: 2 | Pages: 101-103

10.1016/j.pulmoe.2023.09.008 | PMID 38709866 Get It

Creating an Atlas of Normal Tissue for Pruning WSI Patching Through Anomaly Detection
Alsaafin, Areej , Alabtah, Ghazal, Comfere, Nneka I. , Murphree, Dennis H. , Zot, Patricija, Yasir, Saba , García, Joaquín J. , Nejat, Peyman , Mangold, Aaron R. , Tizhoosh, Hamid R.

No container title available | October 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3429527/v1 Get It

Abstract Patching whole slide images (WSIs) is an important task in computational pathology. While most of the are designed to classify or detect the presence of pathological lesions in a WSI, the confounding role and redundant nature of normal histology are generally overlooked. In this paper, we propose and validate the concept of an “atlas of normal tissue” solely using samples of WSIs obtained from normal biopsies. Such atlases can be employed to eliminate normal fragments of tissue samples and hence increase the representativeness the remaining patches. We tested our proposed method by establishing a normal atlas using 107 normal skin WSIs and demonstrated how established search engines like Yottixel can be improved. We used 553 WSIs of cutaneous squamous cell carcinoma to demonstrate the advantage. We also validated our method applied to an external dataset of 451 breast WSIs. The number of selected WSI patches was reduced by 30% to 50% after utilizing the proposed normal atlas while maintaining the same indexing and search performance in leave-one-patient-out validation for both datasets. We show that the proposed concept of establishing and using a normal atlas shows promise for unsupervised selection of the most representative patches of the abnormal WSI patches.
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group
Rabin, Karen R. , Chen, Zhiguo , Ji, Lingyun , Kairalla, John A. , Hitzler, Johann , Carroll, Andrew J. , Heerema, Nyla A. , Borowitz, Michael J., Reshmi, Shalini C. , Bhojwani, Deepa , Maloney, Kelly W. , Mattano, Leonard A. , Larsen, Eric , Salzer, Wanda L. , Carroll, William L. , Raetz, Elizabeth A. , Loh, Mignon L. , Angiolillo, Anne , Ji, Lingyun , Hitzler, Johann K , Yang, Jun J.J. , Carroll, Andrew J , Wood, Brent L , Roberts, Kathryn G , Mullighan, Charles G , Harvey, Richard , Willman, Cheryl , Gastier‐Foster, Julie M. , Rheingold, Susan R , Maloney, Kelly W , Mattano, Leonard A , Schore, Reuven J , Burke, Michael J , Winick, Naomi Joan , Raetz, Elizabeth A , Loh, Mignon L , Hunger, Stephen P , Rabin, Karen R , Devidas, Meenakshi , Wood, Brent L. , Roberts, Kathryn G. , Mullighan, Charles G. , Harvey, Richard C. , Chen, I‐Ming , Willman, Cheryl L. , Hunger, Stephen P.

Journal of Clinical Oncology | October 27, 2023 | Volume: 42 | Issue: 2 | Pages: 218-227

10.1200/jco.23.00389 | PMID 37890117 Get It

PURPOSE Patients with Down syndrome (DS) and B-ALL experience increased rates of relapse, toxicity, and death. We report results for patients with DS B-ALL enrolled on Children's Oncology Group trials between 2003 and 2019. METHODS We analyzed data for DS (n = 743) and non-DS (n = 20,067) patients age 1-30 years on four B-ALL standard-risk (SR) and high-risk trials. RESULTS Patients with DS exhibited more frequent minimal residual disease (MRD) ≥0.01% at end induction (30.8% v 21.5%; P < .001). This difference persisted at end consolidation only in National Cancer Institute (NCI) high-risk patients (34.0% v 11.7%; P < .0001). Five-year event-free survival (EFS) and overall survival (OS) were significantly poorer for DS versus non-DS patients overall (EFS, 79.2% ± 1.6% v 87.5% ± 0.3%; P < .0001; OS, 86.8% ± 1.4% v 93.6% ± 0.2%; P < .0001), and within NCI SR and high-risk subgroups. Multivariable Cox regression analysis of the DS cohort for risk factors associated with inferior EFS identified age >10 years, white blood count >50 × 103/μL, and end-induction MRD ≥0.01%, but not cytogenetics or CRLF2 overexpression. Patients with DS demonstrated higher 5-year cumulative incidence of relapse (11.5% ± 1.2% v 9.1% ± 0.2%; P = .0008), death in remission (4.9% ± 0.8% v 1.7% ± 0.1%; P < .0001), and induction death (3.4% v 0.8%; P < .0001). Mucositis, infections, and hyperglycemia were significantly more frequent in all patients with DS, while seizures were more frequent in patients with DS on high-risk trials (4.1% v 1.8%; P = .005). CONCLUSION Patients with DS-ALL exhibit an increased rate of relapse and particularly of treatment-related mortality. Novel, less-toxic therapeutic strategies are needed to improve outcomes.